# Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma

> **NCT04049175** · PHASE3 · TERMINATED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 810 (actual)

## Conditions studied

- Asthma; Eosinophilic

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B
- **DRUG:** Treatment C
- **DRUG:** Treatment D

## Key facts

- **NCT ID:** NCT04049175
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-28
- **Primary completion:** 2020-10-19
- **Final completion:** 2021-02-01
- **Target enrollment:** 810 (ACTUAL)
- **Why stopped:** An interim analysis run by an independent data monitoring committee (DMC) to assess futility met the protocol-defined futility rules. The DMC recommended to stop the study for futility. The Sponsor issued a notification of early study termination.
- **Last updated:** 2022-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049175, "Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04049175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*